Embecta (EMBC) CEO Dev Kurdikar joins Oliver Renick to give an overview of the company and discuss its 2Q earnings. He also talks about the impact of GLP-1 drugs. He then goes over the diabetes treatment market, as well as other emerging markets. Tune in to find out more about the stock market today.
Market On Close
17 May 2024
SHARE